Wouter Plattel
dr.
As a hematologist I am always looking for new development that might improve patient care. My main research focus is on patients with Hodgkin lymphoma and multiple myeloma. I am involved in both translational and clinical studies. In cooperation with the Pathology, I am active in the field of biomarkers, such as TARC in Hodgkin lymphoma. For the design, development and execution of clinical trials, I am an active member of both international (EORTC) and national (HOVON) organizations. For example, I am the national PI of the EORTC COBRA trial in Hodgkin lymphoma. Moreover, I am co-PI of the translational research in two international trials. In addition, I am part of the Dutch guideline writing committee for Hodgkin lymphoma. In myeloma, I am investigating innovative treatment options to improve outcome.
Working towards harmonization of clinical trial reporting in Hodgkin lymphoma
Published in: HemaSphere
Access to document
10.1002/hem3.70196
document
Carsten Kobe, Philippe Armand, Sven Borchmann, Graham P Collins, Anne-Segolene Cottereau, Justin Ferdinandus, Alex F Herrera, Davide Rossi, Wouter J Plattel, Sally F Barrington, Martin Hutchings
Treatment and outcome of breast implant-associated anaplastic large cell lymphoma: a population-based cohort study in the Netherlands
Published in: Leukemia & lymphoma
Access to document
10.1080/10428194.2025.2530167
document
The optimal treatment of patients with breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) that underwent incomplete resection, have advanced stage disease or relapse after resection remains unknown. We describe the treatment and outcome of all 91 Dutch BIA-ALCL patients up to 2023. Primary outcomes were progression-free survival (PFS) and overall survival (OS). Ann Arbor stage I was frequently encountered (74%) compared to stage II (13%) and stage IV (11%). First-line treatment of stage I patients consisted mostly of surgery (88%). Stage II patients were treated with chemotherapy (CT)...
Frederik O Meeuwes, Mirian Brink, Marjolein W M van der Poel, Y I M Serroukh, Joost S P Vermaat, Gerwin A Huls, Mintsje de Boer, Daphne de Jong, Wouter J Plattel, Marcel Nijland
Consolidation With Second High Dose Therapy and Autologous Stem Cell Transplantation Is Associated With Improved Overall Survival in Patients With Multiple Myeloma in First Relapse
Published in: Clinical lymphoma, myeloma & leukemia
Access to document
10.1016/j.clml.2024.12.010
document
BACKGROUND: High dose chemotherapy and autologous stem cell transplantation (HDT/ASCT) remains the preferred first line consolidation strategy for newly diagnosed multiple myeloma (MM). However, The role of HDT/ASCT in first relapse is uncertain in the context of novel therapies. This study evaluates real-world outcomes of MM patients in first relapse, focusing on the role of consolidative HDT/ASCT. PATIENTS AND METHODS: This retrospective cohort study was conducted at a large tertiary referral center in Northern Netherlands. MM patients who received first-line HDT/ASCT and obtained a good response were included....
Koen M Klomberg, Miriam Gelderloos, Hilde A M Kooistra, Marcel Nijland, Gerwin A Huls, Wilfried W H Roeloffzen, Wouter J Plattel
High-dose therapy followed by autologous stem cell transplantation emerges as the preferred salvage therapy in patients with limited-stage Hodgkin lymphoma progressing/relapsing after initial therapy: A subset analysis of the EORTC/LYSA/FIL H10 trial
Published in: HemaSphere
Access to document
10.1002/hem3.70105
document
Gotti Manuel, Yana Stepanishyna, Tetiana Skrypets, Luigi Marcheselli, Caterina Cristinelli, Barbara Botto, Sanne Tonino, Doriane Cavalieri, Alessandro Pulsoni, Martin Hutchings, Mohammad Hammoud, Catherine Fortpied, Luigi Rigacci, Wouter Plattel, Marc André, Massimo Federico
Molecular profiling of cell-free DNA from classic Hodgkin lymphoma patients identifies potential prognostic clusters and corresponds with disease dynamics
Published in: Annals of Hematology
Access to document
10.1007/s00277-025-06328-8
document
Cell-free DNA (cfDNA) analysis has advantages over tissue analysis for molecular profiling of classic Hodgkin lymphoma (cHL) at diagnosis and offers additional opportunities for sensitive non-invasive disease tracking during treatment. The aim of this study is to correlate cfDNA based molecular profiling with disease characteristics including serum Thymus and Activation Regulated Chemokine (TARC) levels and FDG-PET imaging, which are established markers of disease assessment. cfDNA isolated from plasma samples of 42 cHL patients was analyzed using low coverage whole genome and targeted next-generation sequencing. Patients were clustered in...
Nick Veltmaat, Geok-Wee Tan, Yujie Zhong, Sophie Teesink, Martijn Terpstra, Johanna Bult, Marcel Nijland, Joost Kluiver, Arjan Diepstra, Anke van den Berg, Wouter J Plattel